Infrastructure company Cellnex has partnered with Harrow Council as part of an agreement to bolster mobile connectivity ...

Alix E. Harrow's new book follows a weary historian pulled into a magical time loop with the legendary knight he’s adored ...

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

North London Council announces part a partnership with telecoms infrastructure operator to deploy small cell technology ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that man ...

Harrow, Inc. has secured a key win as CVS’s pharmacy benefit manager replaced Xiidra with Harrow’s dry eye drug Vevye on its Tier 1 formulary, and the company recently presented at BTIG Ophthalmology ...

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

Discover why Harrow Inc. (HROW) is a strong buy in 2024—explosive growth from Vevye, rising margins, and a $175 price target.

Please provide your email address to receive an email when new articles are posted on . Harrow will inherit MELT-300, a sublingually delivered sedation product. The company plans to submit a new drug ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) ...